ClinicalTrials.gg
CompletedNCT01620489Updated Mar 19, 2019Results posted

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 97 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-19.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
37th of 151
279 · median 62
Started
2012
with 20 others
Phase 3
45 of 151
1 open now
Registered
65th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 65th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.

The trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 279 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with type 2 diabetes with stable diabetes treatment (unchanged medication and unchanged dose) for 90 days prior to the screening visit including: Monotherapy or any duo-combinations of metformin and/or SUs and/or pioglitazone. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines. Or Monotherapy or any combinations of metformin and/or pioglitazone and/or basal or premix insulin. Insulin adjustments (total daily dose) below or equal to 10% within 90 days prior to the screening visit as confirmed by the investigator are acceptable. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines. Combination of pioglitazone and insulin should be used with caution and according to local labelling or guidelines
  • 7-10% (both inclusive)
  • Moderate renal impairment diagnosed more than 90 days prior to the screening visit and confirmed by an (glomerular filtration rate) of 30-59 mL/min/1.73 m2 per MDRD (modification of diet in renal disease) formula at the screening visit
  • (BMI) 20-45 kg/m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
  • Treatment with antidiabetic medication(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. Previous short-term (below or equal to 7 days in total) treatment with rapid-or short-acting insulin in connection with intercurrent illness is allowed at the discretion of the investigator
  • Impaired liver function, defined as ALAT () above or equal to 2.5 times upper normal limit
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Within the past 180 days any of the following: Episode of unstable angina, acute coronary event, cerebral stroke/ (TIA) or other significant cardiovascular event (including e.g. arrhythmias or conduction delays on (electrocardiogram))
  • Heart failure defined as (NYHA) class IV
  • A systolic blood pressure above or equal to 180 mmHg or a diastolic blood pressure above or equal to 100 mmHg
  • Rapidly progressing renal disease (e.g., acute glomerulonephritis) at the discretion of the investigator
  • Use of treatment within 90 days prior to screening
  • Diagnosis or treatment for cancer in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
  • Proliferative retinopathy or maculopathy requiring acute treatment as judged by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Lira 1.8 mg

    Drug: liraglutide

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • 1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.

  • Drugplacebo

    Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.

07

What researchers measure

Primary outcomes

  1. Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)

    Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment

    Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.

    Time frame: At week 26

  2. Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment

    Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.

    Time frame: At week 26

  3. Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles

    SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.

    Time frame: Week 0, week 26

  4. Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)

    Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.

    Time frame: Week 0, week 26

  5. Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)

    Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.

    Time frame: Week 0, week 26

08

Results

Posted Oct 30, 2014

Participant flow

This trial was conducted in France, Poland, Russian Federation, Ukraine, United Kingdom, and the United States of America.

Participant flow — Overall Study
MilestoneLira 1.8 mgPlacebo
Started140139
Exposed140137
Completed105105
Not completed3534
Withdrew: Adverse event174
Withdrew: Protocol violation03
Withdrew: Withdrawal criteria1725
Withdrew: Unclassified12

Outcome measures

PrimaryEstimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)

Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage (%)
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)
percentage (%)Lira 1.8 mgPlacebo
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)-1.05 ± 0.8944-0.38 ± 0.8797
Statistical analysis
  • Lira 1.8 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Adjustment for multiple comparisons was not used since there was only one primary endpoint.) · Estimated treatment difference: -0.66 · 95% CI -0.90 to -0.43
SecondaryEstimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment

Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.

Time frame:
At week 26
Reported as:
Number · percentage of patients
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment
percentage of patientsLira 1.8 mgPlacebo
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment46.0315.99
Statistical analysis
  • Lira 1.8 mg vs Placebo · Regression, Logistic · p = <0.0001 (Not adjusted for multiple comparisons) · Estimated odds ratio: 4.48 · 95% CI 2.46 to 8.18
SecondaryEstimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment

Calculated as estimated percentage of subjects achieving HbA1c \<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.

Time frame:
At week 26
Reported as:
Number · percentage of patients
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment
percentage of patientsLira 1.8 mgPlacebo
Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment33.2311.23
Statistical analysis
  • Lira 1.8 mg vs Placebo · Regression, Logistic · p = <0.0001 (Not adjusted for multiple comparisons) · Estimated odds ratio: 3.94 · 95% CI 2.12 to 7.30
SecondaryEstimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles

SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles
mmol/LLira 1.8 mgPlacebo
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles-1.59 ± 2.480-0.51 ± 2.391
Statistical analysis
  • Lira 1.8 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Not adjusted for multiple comparisons) · Estimated treatment difference: -1.08 · 95% CI -1.58 to -0.58
SecondaryEstimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)

Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.

Time frame:
Week 0, week 26
Reported as:
Mean · kg/m^2
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)
kg/m^2Lira 1.8 mgPlacebo
Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)-0.88 ± 1.3214-0.38 ± 1.1679
Statistical analysis
  • Lira 1.8 mg vs Placebo · Mixed Models Analysis · p = = 0.0022 · Estimated treatment difference: -0.51 · 95% CI -0.83 to -0.18Not adjusted for multiple comparisons
SecondaryEstimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)

Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · mL/min/1.73m˄2
Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)
mL/min/1.73m˄2Lira 1.8 mgPlacebo
Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)0.99 ± 0.171.01 ± 0.19
Statistical analysis
  • Lira 1.8 mg vs Placebo · Mixed Models Analysis · p = = 0.3575 (Not adjusted for multiple comparisons) · Estimated treatment ratio: 0.98 · 95% CI 0.94 to 1.02

Adverse events

Collected over The adverse events were collected from Week 0 to Week 27±3 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lira 1.8 mg—14/140 (10%)73/140 (52.1%)
Placebo—15/137 (10.9%)49/137 (35.8%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventLira 1.8 mgPlacebo
SyncopeNervous system disorders2/1400/137
AnaemiaBlood and lymphatic system disorders0/1401/137
Acute myocardial infarctionCardiac disorders1/1401/137
Abdominal pain lowerGastrointestinal disorders0/1401/137
Gastric ulcer haemorrhageGastrointestinal disorders0/1401/137
Gastrointestinal haemorrhageGastrointestinal disorders0/1401/137
Autoimmune hepatitisHepatobiliary disorders0/1401/137
Arteriosclerotic gangreneInfections and infestations0/1401/137
OsteomyelitisInfections and infestations0/1401/137
FallInjury, poisoning and procedural complications0/1401/137
Most frequent other events
Most frequent other events
EventLira 1.8 mgPlacebo
NauseaGastrointestinal disorders30/1406/137
Lipase increasedInvestigations21/14012/137
VomitingGastrointestinal disorders17/1403/137
NasopharyngitisInfections and infestations7/14016/137
DiarrhoeaGastrointestinal disorders10/1404/137
Glomerular filtration rate decreasedInvestigations9/1407/137
Renal impairmentRenal and urinary disorders7/1408/137
ConstipationGastrointestinal disorders8/1402/137
Upper respiratory tract infectionInfections and infestations4/1407/137
HeadacheNervous system disorders7/1404/137

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lira 1.8 mgPlaceboTotal
Mean68.0 ± 8.366.3 ± 8.067.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Lira 1.8 mgPlaceboTotal
Female6572137
Male7565140
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)Lira 1.8 mgPlaceboTotal
Mean9.48 ± 3.2709.27 ± 2.8429.38 ± 3.061
Glycosylated haemoglobin (%)(HbA1c)
Glycosylated haemoglobin (%)(HbA1c)(Percent (%) glycosylated haemoglobin)Lira 1.8 mgPlaceboTotal
Mean8.08 ± 0.7928.00 ± 0.8538.04 ± 0.823
09

Study locations

97 sites
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Torrance, California 90502, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Saint Petersburg, Florida 33711, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30303, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Avon, Indiana 46123, United States
  • Novo Nordisk Investigational Site
    Franklin, Indiana 46131, United States
  • Novo Nordisk Investigational Site
    Greenfield, Indiana 46140, United States
  • Novo Nordisk Investigational Site
    Muncie, Indiana 47304, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Springfield, Massachusetts 01199, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Southfield, Michigan 48034-7661, United States
  • Novo Nordisk Investigational Site
    Great Falls, Montana 59405, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Rosedale, New York 11422, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Mooresville, North Carolina 28117, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Mason, Ohio 45040-6815, United States
  • Novo Nordisk Investigational Site
    Wadsworth, Ohio 44281-9236, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Novo Nordisk Investigational Site
    McMurray, Pennsylvania 15317, United States
  • Novo Nordisk Investigational Site
    Norristown, Pennsylvania 19401, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    East Providence, Rhode Island 02914, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404-1192, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Lubbock, Texas 79423, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77479, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23219, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23294, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23298, United States
  • Novo Nordisk Investigational Site
    Winchester, Virginia 22601, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    LA ROCHE-sur-YON cedex 9, 85295, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Pointe À Pitre, 97159, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67000, France
  • Novo Nordisk Investigational Site
    Bialystok, 15-381, Poland
  • Novo Nordisk Investigational Site
    Bialystok, 15-435, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-546, Poland
  • Novo Nordisk Investigational Site
    Katowice, 40-767, Poland
  • Novo Nordisk Investigational Site
    Krakow, 31-261, Poland
  • Novo Nordisk Investigational Site
    Poznan, 60-111, Poland
  • Novo Nordisk Investigational Site
    Poznan, 60-569, Poland
  • Novo Nordisk Investigational Site
    Zabrze, 41-800, Poland
  • Novo Nordisk Investigational Site
    Barnaul, 656045, Russian Federation
  • Novo Nordisk Investigational Site
    Kazan, 420043, Russian Federation
  • Novo Nordisk Investigational Site
    Kursk, 305035, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 123448, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127411, Russian Federation
  • Novo Nordisk Investigational Site
    Nizhniy Novgorod, 603126, Russian Federation
  • Novo Nordisk Investigational Site
    Penza, 440026, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194358, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 195257, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    Samara, 443067, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410031, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410039, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410053, Russian Federation
  • Novo Nordisk Investigational Site
    Smolensk, 214019, Russian Federation
  • Novo Nordisk Investigational Site
    Volgograd, 400138, Russian Federation
  • Novo Nordisk Investigational Site
    Kharkiv, 61000, Ukraine
  • Novo Nordisk Investigational Site
    Kiev, 04053, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 04114, Ukraine
  • Novo Nordisk Investigational Site
    Vinnytsia, 21010, Ukraine
  • Novo Nordisk Investigational Site
    Zaporizhia, 69600, Ukraine
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2RW, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE5 4PW, United Kingdom
  • Novo Nordisk Investigational Site
    Letchworth, SG6 4UB, United Kingdom
  • Novo Nordisk Investigational Site
    London, E1 2EF, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE5 9RT, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
10

References and documents

Publications

  • Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syren A, Umpierrez GE. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016 Feb;39(2):222-30. doi: 10.2337/dc14-2883. Epub 2015 Dec 17. PubMed 26681713 ↗
  • Zobel EH, von Scholten BJ, Goldman B, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Diabetes Obes Metab. 2019 May;21(5):1261-1265. doi: 10.1111/dom.13638. Epub 2019 Feb 22. PubMed 30663196 ↗
  • Kim JD, Park CY, Cha BY, Ahn KJ, Kim IJ, Park KS, Lee HW, Min KW, Won JC, Chung MY, Kim JT, Kang JG, Park SW. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes. Clin Ther. 2018 May;40(5):752-761.e2. doi: 10.1016/j.clinthera.2018.04.002. Epub 2018 May 3. PubMed 29729957 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Aug 2013, 14 months.

Results were first posted in Oct 2014, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2012
First posted
Jun 15, 2012
StartActual
Jun 14, 2012
Primary completionActual
Aug 20, 2013
CompletionActual
Aug 20, 2013
Results first posted
Oct 30, 2014
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01620489
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 15, 2012
Start date
Jun 14, 2012
Primary completion
Aug 20, 2013
Completion
Aug 20, 2013
Results posted
Oct 30, 2014
Last update
Mar 19, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion